PHP May Increase Survival in Patients with Liver Metastases

“Percutaneous hepatic perfusion increased hepatic progression free and overall survival rates in patients with liver metastases from melanoma vs. patients who underwent yttrium-90 therapy, according to data presented at the 2015 Society of Surgical Oncology Annual Cancer Symposium.

“Jonathan S. Zager, MD, FACS, director of regional therapies and chair of graduate medical education at Moffitt Cancer Center in Tampa, and colleagues, including Andrea M. Abbott, MD, of surgical oncology at Moffitt Cancer Center, analyzed data of 30 patients with cutaneous or uveal melanoma that metastasized to the liver after treatment with percutaneous hepatic perfusion (PHP), yttrium-90 (Y90) or chemoembolization using melphalan hydrochloride for injection with the Delcath Hepatic Delivery System (Melphalan/HDS, Delcath Systems, Inc.). The Melphalan/HDS is a system designed to supply high-dose chemotherapy to the liver while controlling systemic exposure, according to the Delcath website.”